Matches in SemOpenAlex for { <https://semopenalex.org/work/W4238033397> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W4238033397 endingPage "4054" @default.
- W4238033397 startingPage "4054" @default.
- W4238033397 abstract "4054 Background: The epidermal growth factor receptor (EGFR) is highly expressed in esophageal cancer and is associated with advanced disease, resistance to chemotherapy and radiotherapy, and poor prognosis. Furthermore, upregulation of cyclooxygenase 2 (COX2) has been observed in esophageal cancer, suggesting that COX2 may also play a role in esophageal carcinogenesis. In preclinical studies, COX2 inhibition decreased cell growth and increased apoptosis in esophageal cancer cells (Cancer Res 2000; 60: 5767–72). In this study, we examined the efficacy and tolerability of the combination of the orally active EGFR tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) with the COX2 inhibitor celecoxib (Celebrex) in patients with advanced esophageal cancer without previous exposure to chemotherapy. Methods: In this single-arm Phase II trial, patients received gefitinib (250 mg/day) and celecoxib (400 mg bid). Study objectives included evaluating tumor response, progression-free and overall survival, and tolerability. Results: To date, 15 patients have been recruited; 3 with squamous-cell carcinoma and 12 with adenocarcinoma. Fourteen patients were evaluable for response; 1 was not evaluable due to death from gastrointestinal bleeding as a result of tumor progression. At first evaluation after 2 months of treatment, 10 patients (71%) had disease progression while 3 (21%) had stable disease and are in follow-up with a mean time of 5.5 months. One patient was lost to follow-up and not evaluable. No radiologic remission was observed in any patient. All 15 patients were evaluable for tolerability. The most frequently occurring adverse event was acneiform skin rash, grade 1/2 in 6 patients (40%). No treatment-related grade 3/4 toxicities were seen. Conclusions: Combination treatment with gefitinib and celecoxib was generally well tolerated. Although 3 patients had disease stabilization, the lack of efficacy in this small study might preclude further clinical investigation of this combination. ‘Iressa’ is a trademark of the AstraZeneca group of companies. No significant financial relationships to disclose." @default.
- W4238033397 created "2022-05-12" @default.
- W4238033397 creator A5009881202 @default.
- W4238033397 creator A5028979343 @default.
- W4238033397 creator A5034058335 @default.
- W4238033397 creator A5057990474 @default.
- W4238033397 creator A5063117037 @default.
- W4238033397 creator A5065849835 @default.
- W4238033397 creator A5082821365 @default.
- W4238033397 date "2004-07-15" @default.
- W4238033397 modified "2023-09-27" @default.
- W4238033397 title "Evaluation of the antitumor activity of gefitinib (ZD1839) in combination with celecoxib in patients with advanced esophageal cancer" @default.
- W4238033397 doi "https://doi.org/10.1200/jco.2004.22.14_suppl.4054" @default.
- W4238033397 hasPublicationYear "2004" @default.
- W4238033397 type Work @default.
- W4238033397 citedByCount "2" @default.
- W4238033397 crossrefType "journal-article" @default.
- W4238033397 hasAuthorship W4238033397A5009881202 @default.
- W4238033397 hasAuthorship W4238033397A5028979343 @default.
- W4238033397 hasAuthorship W4238033397A5034058335 @default.
- W4238033397 hasAuthorship W4238033397A5057990474 @default.
- W4238033397 hasAuthorship W4238033397A5063117037 @default.
- W4238033397 hasAuthorship W4238033397A5065849835 @default.
- W4238033397 hasAuthorship W4238033397A5082821365 @default.
- W4238033397 hasConcept C121608353 @default.
- W4238033397 hasConcept C126322002 @default.
- W4238033397 hasConcept C143998085 @default.
- W4238033397 hasConcept C197934379 @default.
- W4238033397 hasConcept C2776694085 @default.
- W4238033397 hasConcept C2778375690 @default.
- W4238033397 hasConcept C2778570526 @default.
- W4238033397 hasConcept C2779438470 @default.
- W4238033397 hasConcept C2779742542 @default.
- W4238033397 hasConcept C2780580887 @default.
- W4238033397 hasConcept C71924100 @default.
- W4238033397 hasConcept C90924648 @default.
- W4238033397 hasConceptScore W4238033397C121608353 @default.
- W4238033397 hasConceptScore W4238033397C126322002 @default.
- W4238033397 hasConceptScore W4238033397C143998085 @default.
- W4238033397 hasConceptScore W4238033397C197934379 @default.
- W4238033397 hasConceptScore W4238033397C2776694085 @default.
- W4238033397 hasConceptScore W4238033397C2778375690 @default.
- W4238033397 hasConceptScore W4238033397C2778570526 @default.
- W4238033397 hasConceptScore W4238033397C2779438470 @default.
- W4238033397 hasConceptScore W4238033397C2779742542 @default.
- W4238033397 hasConceptScore W4238033397C2780580887 @default.
- W4238033397 hasConceptScore W4238033397C71924100 @default.
- W4238033397 hasConceptScore W4238033397C90924648 @default.
- W4238033397 hasIssue "14_suppl" @default.
- W4238033397 hasLocation W42380333971 @default.
- W4238033397 hasOpenAccess W4238033397 @default.
- W4238033397 hasPrimaryLocation W42380333971 @default.
- W4238033397 hasRelatedWork W1110380345 @default.
- W4238033397 hasRelatedWork W1618072806 @default.
- W4238033397 hasRelatedWork W1969875143 @default.
- W4238033397 hasRelatedWork W1990407560 @default.
- W4238033397 hasRelatedWork W2025037368 @default.
- W4238033397 hasRelatedWork W2062860758 @default.
- W4238033397 hasRelatedWork W2098447324 @default.
- W4238033397 hasRelatedWork W2151126163 @default.
- W4238033397 hasRelatedWork W2388106736 @default.
- W4238033397 hasRelatedWork W3034543458 @default.
- W4238033397 hasVolume "22" @default.
- W4238033397 isParatext "false" @default.
- W4238033397 isRetracted "false" @default.
- W4238033397 workType "article" @default.